1 Potential gains in health-adjusted life expectancy by reducing burden of non-

2 communicable diseases: a population-based study

- 3 Jun-Yan Xi¹, Wang-Jian Zhang¹, Zhuo Chen², Yan-Ting Zhang¹, Li-Chang Chen¹, Yu-Qin
- 4 Zhang¹, Xiao Lin^{1,*}, Yuan-Tao Hao^{1,3,4,5,*}.
- 5 1 Department of Medical Statistics, School of Public Health, Sun Yat-sen University,
- 6 Guangzhou 510080, China;
- 7 2 Department of Health Policy and Management, College of Public Health, University of
- 8 Georgia, Athens, Georgia 30602, USA;
- 9 3 Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing
- 10 100191, China;
- 11 4 Sun Yat-sen Global Health Institute, Sun Yat-sen University, Guangzhou 510080, China;
- 12 5 Center for Health Information Research, Sun Yat-sen University, Guangzhou 510080, China.
- 13

```
14 *Correspondence to:
```

- 15 Yuan-Tao Hao, PhD
- 16 Peking University Center for Public Health and Epidemic Preparedness & Response,
- 17 Xueyuan Road, Haidian District, Beijing 100191, China;
- 18 Department of Medical Statistics, School of Public Health, Sun Yat-sen University,
- 19 74th Zhongshan 2nd Rd, Yuexiu District, Guangzhou 510080, China.
- 20 Tel: +86-13610271412
- 21 Email: haoyt@bjmu.edu.cn

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

²²

- 23 Xiao Lin, PhD
- 24 Department of Medical Statistics, School of Public Health, Sun Yat-sen University,
- 25 74th Zhongshan 2nd Rd, Yuexiu District, Guangzhou 510080, China.
- 26 Tel: +86-15875327398
- 27 Email: linx87@mail.sysu.edu.cn
- 28

29 Abstract

30 Background

31 The United Nations Sustainable Development Goals (SDGs) target 3.4 aims to reduce premature mortality attributable to non-communicable diseases (NCDs) by one-third of their 32 33 2015 levels by 2030. Although meeting this target leads to longevity, survivors may suffer from 34 long-term disability caused by NCDs. This paper quantifies the potential gains in healthadjusted life expectancy for people aged 30-70 years (HALE $_{[30-70)}$) by examining the reductions 35 36 in disability in addition to premature mortality. Additionally, we also assessed the feasibility of 37 meeting the SDGs target 3.4. Methods 38 We extracted data from the Global Burden of Disease Study 2019 for all NCDs and four major 39 40 NCDs (cancers, cardiovascular diseases, chronic respiratory diseases, and diabetes mellitus) in 188 countries from 1990 to 2019. Bayesian age-period-cohort models were used to predict 41 42 possible premature mortality in 2030. The life table was used to estimate the unconditional 43 probability of death and HALE_[30-70]. Estimates of the potential gains in HALE_[30-70] were based 44 on three alternative future scenarios: a) eliminating all premature deaths and disability from a 45 specific cause, b) meeting SDGs target 3.4, and survivors' disability is eliminated, and c) 46 meeting SDGs target 3.4, but survivors remain disabled for the rest of their lives. 47 Results

In 2030, the unconditional probability of premature mortality for four major NCDs in most countries remained at more than two-thirds of the 2015 baseline. In all scenarios, the highincome group has the greatest potential gains in $HALE_{[30-70)}$, above the global average of

51	HALE _{[30-70)} . In scenario A, the potential gains in $HALE_{[30-70)}$ of reducing premature mortality
52	for four major NCDs are significantly lower than those for all NCDs (range of difference for
53	all income groups: 2.88 - 3.27 years). In scenarios B and C, the potential gains of $HALE_{[30-70)}$
54	in reducing premature mortality for all NCDs and the four major NCDs are similar (scenario B:
55	0.14 - 0.22, scenario C: 0.05 - 0.19). In scenarios A and B, countries from the high-income
56	group have the greatest potential gains in $HALE_{[30-70)}$ from cancer intervention, whilst countries
57	from the other income groups result in a greater possible $HALE_{[30-70)}$ gains from cardiovascular
58	diseases control. In scenario C, countries from each income group have the largest potential
59	gains in $HALE_{[30-70)}$ from diabetes reduction and chronic respiratory diseases prevention.
60	Conclusions
61	Achieving SDGs target 3.4 remains challenging for most countries. The elimination of
62	disability among the population who benefit from the target could lead to a sizable improvement
63	in HALE $_{[30-70)}$. Reducing premature death and disability at once and attaching equal importance
64	to each to in line with the WHO goal of "leaving no one behind".
65	Keywords: Bayesian age-period-cohort model; Global health; Health-adjusted life expectancy;
66	Non-communicable diseases; Sustainable Development Goals.
67	Funding
68	Guangdong Basic and Applied Basic Research Foundation (2020A1515011294)
69	Yuan-Tao Hao
70	Guangdong Basic and Applied Basic Research Foundation (2020A1515110230)
71	Xiao Lin
72	Guangdong Basic and Applied Basic Research Foundation (2021A1515011765)

73 Xiao Lin

74 China Postdoctoral Science Foundation (grant 2021M693594)

- 75 Xiao Lin
- 76 Additionally, Professor Yuan-Tao Hao gratefully acknowledges the support of K.C.Wong
- 77 Education Foundation.
- 78 The funders had no role in study design, data collection and interpretation, or the decision to
- 79 submit the work for publication.

80

81 Introduction

82	Reducing the burden of disease caused by non-communicable diseases (NCDs) is a critical
83	target of global public health efforts. According to the World Health Statistics 2021 released by
84	the World Health Organization (WHO), seven of the top ten causes of death in 2019 were NCDs,
85	and the proportion of mortalities attributable to NCDs increased from 60.8% in 2000 to 73.6%
86	in 2019 ^[1] . WHO focuses on four categories of NCDs, including cardiovascular diseases (CVD),
87	cancers, chronic respiratory diseases (CRD), and diabetes mellitus, which are the leading causes
88	of premature death from NCDs ^[2] . Although the total mortality rate for the four NCDs is
89	declining, the total number of deaths associated with them is still increasing ^[1] . In addition, the
90	impact of NCDs is particularly severe in low- and middle-income countries, where more than
91	three-quarters of global NCD deaths occur. The burden of NCDs in these countries is predicted
92	to continue increasing in the coming decades ^[2] . Reducing premature mortality (the
93	unconditional probability of dying from the four major NCDs between the ages of 30 and 70)
94	by a third from 2015 levels by 2030 is on the United Nations (UN) agenda as Sustainable
95	Development Goals (SDGs) target 3.4 ^[3] . The NCD Countdown 2030 Report proposed more
96	comprehensive indicators and committed to leaving no one behind ^[4,5] . Although members of
97	the UN General Assembly have stepped up their investment in health and begun to develop
98	framework legislation to strengthen national governance of NCDs, slow progress in NCDs
99	prevention and control may make it difficult to meet SDGs target 3.4 ^[6-8] . Trend analysis of
100	regional and country-level premature mortality attributable to NCDs from a global health
101	perspective provides an intuitive assessment of progress towards meeting SDGs target 3.4 ^[9,10] .
102	Meeting the ambitious SDGs target 3.4 would have substantial effects on life expectancy

103	globally ^[9] . However, neglected disability attributed to the four major NCDs may lead to
104	unhealthy longevity ^[11,12] . Since 1990, there has been a marked shift towards a greater
105	proportion of burden due to years lived with disability (YLDs) from NCDs ^[13] . Many excluded
106	disabilities are amenable to prevention and treatment, and some NCDs deaths can be postponed.
107	Therefore, the global agenda for promoting human prosperity should be expanded to
108	rehabilitate the disability of survivors who benefit from SDGs target 3.4. Health-adjusted life
109	expectancy can effectively estimate the healthy life span lost due to disability by decomposing
110	life expectancy into healthy and disability components ^[14] . Assessing the potential of reducing
111	disability in survivors to extend health-adjusted life expectancy under the framework of SDGs
112	target 3.4 is key to highlighting the public health and socioeconomic significance of this
113	expanded target.
114	In this study, we grouped 188 countries according to the World Bank income classifications.
115	We fitted Bayesian age-period-cohort (BAPC) models based on historical premature mortality
116	trends from 1990 to 2019 and assessed the feasibility of meeting SDGs target 3.4 by 2030 based
117	on model projections. In addition, we considered three alternative future scenarios in 2030 to
118	quantify the potential gains in health-adjusted life expectancy between ages 30 and 70 years
119	(HALE $_{[30-70)}$) by reducing disability and premature mortality from non-communicable diseases.
120	
121	Methods

122 Data sources

123 We obtained standard epidemiological measures from the Global Burden of Disease Study 2019

124 (GBD 2019) result for five cause clusters by country and year, including all-cause mortalities

125	or cause-specific mortalities (non-communicable diseases, neoplasms, cardiovascular diseases,
126	chronic respiratory diseases, and diabetes mellitus), demographics, years of life lost (YLLs)
127	and years lived with disability (YLDs). GBD 2019 is a multinational collaborative study that
128	estimates the burden of diseases in countries around the world and produces summary measures
129	of health. The study updates the datasets annually, thus consistent comparisons could be made
130	between sex, age, and across locations for 1990-2019. The data sources and methods are
131	described elsewhere ^[13-15] . All datasets are available via the GBD 2019 website ^[16] .
132	Population projections for 2020-2030 were obtained from the World Population Prospects 2019.
133	This dataset provides the median, 80%, and 95% prediction intervals with quinquennial
134	population by country, sex, and five-year age groups (0-4, 5-9, 10-14,, 95-99, 100+). World
135	Population Prospects 2019 is probabilistic population projections produced and displayed by
136	the United Nations Population Division based on the Bayesian hierarchical models for the total
137	fertility rate and life expectancy at birth, with detailed methods reported previously ^[17,18] . The
138	dataset is available online ^[19] .
139	In addition, we grouped selected countries based on the World Bank's classification, including
140	high-income countries, upper-middle-income countries, lower-middle-income countries, and
141	low-income countries ^[20] . This study complies with the Guidelines for Accurate and Transparent
142	Health Estimates Reporting (GATHER) statement ^[21] .

143

144 Analytical strategies

The Bayesian APC models were fitted by NCDs cluster, gender, and country to predict possible
 NCDs-attributable premature mortality in 2030, based on historical trends in premature

mortality from 1990 to 2019. The Bayesian APC models, which incorporates age, period, and 147 cohort heterogeneity, were developed with R software, using the BAPC package (R version 148 149 4.1.1)^[22]. BAPC package builds upon Integrated Nested Laplace Approximations (INLA) and addresses complex convergence concerns introduced by Markov chain Monte Carlo 150 151 (MCMC)^[23]. The aim is to efficiently forecast future rates and counts within a fully Bayesian 152 inference setting. Specifically, we chose to use second-order random walk priors (RW2) for age, period, and cohort effect, which penalizes deviations from a linear trend with better predictions. 153 154 The hyper prior for the precision (inverse variance) in the random walk priors is a Gamma 155 distribution with parameters a and b, and weak hyperparameters (a=1, b=0.00005) were set to smooth the estimation^[24]. The dataset used for age-standardization was obtained from GBD 156 2019 global population estimates. 157 158 We estimated the potential gains in $HALE_{[30-70]}$ by applying cause-deleted life table methods to cause-specific baseline premature mortality reported in 2015, using methods developed by 159

161 to calculate the cause-deleted death probability and cause-deleted disability prevalence, as 162 described in previous studies^[27,28], which is calculated assuming independence among causes 163 of death and disability. We considered three alternative future scenarios of premature mortality

Sullivan^[14,25,26]. The key to estimating the potential gain in HALE_[30-70] from a specific cause is

164 reduction from what was observed in the baseline year 2015 as in the following.

160

a) Eliminating all premature deaths and disability from a specific cause to assess the maximum potential to increase $HALE_{[30-70)}$, which reflects all health burdens of the specific cause.

167
$$CEHALE_{[30-70]} = \frac{1}{l_j} \left[\sum_{i=x}^{w} L_j \times \{1 - (YLD_i - YLD_j)\} \right]$$

168 b) Based on the expanded target, the unconditional probability of premature death from a

169 specific cause is reduced by one-third, and survivors' disability is eliminated, which reflects the

170 potential to increase $HALE_{[30-70)}$.

171
$$CEHALE_{[30-70)} = \frac{1}{l_j} \left[\sum_{i=x}^{w} L_j \times \{1 - YLD_i\} \right]$$

c) Based on SDGs target 3.4, the unconditional probability of premature death from a specific
cause is reduced by one-third, but survivors are disabled for the rest of their lives, which reflects

the healthy years of life lost to disability due to the specific cause and is used as a reference.

175
$$CEHALE_{[30-70)} = \frac{1}{l_j} \left[\sum_{i=x}^{w} L_j \times \left\{ 1 - \left(YLD_i + \frac{1}{3} \times YLL_j \right) \right\} \right]$$

176 Where l_j is the number of persons surviving to the exact age x_i after eliminating or reducing

177 by a third number of deaths attributed to the cause j, L_j is the number of person-years lived in

178 the age interval (x_i, x_{i+1}) after eliminating the number of person-years attributed to cause j,

179 YLD_i and YLD_i is years lived with disability due to all-cause and specific-cause in the age

- 180 interval (x_i, x_{i+1}) , YLL_i is years of life lost due to specific-cause in the age interval (x_i, x_{i+1}) ,
- 181 and ω is the last age group in the life table.

182 The difference between $CEHALE_{[30-70)}$ and $HALE_{[30-70)}$ is the potential gain. We computed the

183 95% uncertainty intervals (UIs) by propagating the uncertainty from the GBD 2019 estimates.

184

185 Results


186 Trends in age-standardized premature mortality for all NCDs and four major NCDs in

187 **people aged 30-70, 1990-2030**

188 From 1990 to 2030, the age-standardized premature mortality of all NCDs showed varying

189 degrees of decline (ranging from 24.8% to 45.3%). Specifically, high- and upper-middle-

190	income countries had higher age-standardized premature mortality due to cancers in 1990 than
191	other countries, but the relative decline in this rate over three decades was more than 30 percent
192	(35.1%, 31.9%), higher than lower-middle- and low-income countries (4.5%, 9.9%). The
193	relative decline in age-standardized premature mortality from CVD was more than 50 percent
194	in high- and upper-middle-income countries (58.0%, 53.9%) and close to 30 percent in lower-
195	middle- and low-income countries (27.4%, 29.6%). The relative decline in age-standardized
196	premature mortality attributable to CRD was greatest in upper-middle-income countries (78.6%)
197	and smallest in high-income countries (35.1%), but the latter already had the lowest premature
198	mortality in 1990. Although the global age-standardized premature mortality for the above three
199	major NCDs decreased, the age-standardized premature mortality for diabetes mellitus
200	increased by 9.9%. The age-standardized premature mortality rate for diabetes in other
201	countries showed a downtrend, except for lower-middle-income countries. Age-standardized
202	premature mortality due to cancers is projected to remain higher in high- and upper-middle-
203	income countries until 2030 compared with lower-middle- and low-income countries, while
204	age-standardized premature mortality due to the three major NCDs are expected to be low
205	(figure 1).





207 Fig.1 Trends in age-standardized premature mortality for all NCDs and four major NCDs

208 in people aged 30-70, 1990-2030

209

210 Changes in unconditional probability of premature death for four major NCDs in 2030

compared with 2015

212 Figure 2 shows the estimated unconditional probability of premature death reduction 213 attributable to four major NCDs by 2030 compared to 2015. The global premature mortality in 214 2030 is only marginally lower than in 2015 and still far from the goal of reducing it by a third 215 (premature mortality: 0.024 in 2015, 0.023 in 2030; 0.016 in SDGs target 3.4). In 2030, the unconditional probability of premature mortality for four major NCDs in most countries 216 remained at more than two-thirds of the 2015 baseline. While high-income countries will 217 218 struggle to reduce premature mortality by a third, their baseline for 2015 and projected for 2030 are well below global. For the other three income groups, lower income was associated with 219 220 higher premature mortality. The unconditional probability of premature death for four major 221 NCDs for 2015 and 2030 and their proportional changes with 95% UIs are provided in the appendix (table S1). 222






Fig.2 Changes in unconditional probability of premature death for four major NCDs in

225 **2030 compared with 2015**

In the stack bar graph, gray and black columns are the unconditional probabilities of premature

227	mortality for the four major NCDs in 2015 and 2030, respectively. The red dots represent 2/3
228	of the unconditional probability of premature mortality at baseline in 2015. The red dotted lines,
229	blue dotted lines, and red solid lines represent the SDG target 3.4 reference value, the projected
230	value for 2030, and the baseline value for 2015 respectively.
231	
232	HALE _{[30-70)} and age-standardized YLDs for all NCDs and four major NCDs in people
233	aged 30-70, 2015
234	In 2015, the HALE $_{[30-70)}$ of the global population was 25.14 years of the 40-year lifespan that
235	corresponds to ages 30-70 years. The $HALE_{[30-70)}$ in high- and upper-middle-income countries
236	(28.01 years, 25.71 years) were above the world level, while lower-middle- and low-income
237	countries (22.54 years, 21.35 years) were below it. The proportion of YLDs attributed to all
238	NCDs ranges from 88.2% in high-income countries to 75.1% in low-income countries. Overall,
239	the proportion of YLDs attributed to diabetes mellitus was the highest of the four major NCDs,
240	and the opposite was true for cancers. Cancers had a higher proportion of YLDs in high- and
241	upper-middle-income countries than in lower-middle- and low-income countries. Lower-
242	middle-income countries had the highest proportion of YLDs in CRD. Notably, upper-middle-
243	income countries had the lowest proportion of YLDs for CRD, but the leading cause of YLDs
244	was CVD. On the contrary, the proportion of YLDs in CVD in other countries was lower than
245	the world level (table 1). The average HALE and age-standardized YLDs between 30 years and
246	70 years with 95% UIs are provided in the appendix (table S2).
247	Table 1 HALE _[30-70] and age-standardized YLDs for all NCDs and four major NCDs in

248 **people aged 30-70, 2015**

		Global	High- income	Upper- middle-	Lower- middle-	Low- income
			••••	income	income	
HALE[30-70)		25.14	28.01	25.71	22.54	21.35
Attributable	e age-standardi	zed YLDs	(per 100 000))		
All-		14087.2	14646.2	12940.2	15091.9	14839.6
Cause		(100%)	(100%)	(100%)	(100%)	(100%)
All		11808.2	12916.1	11169.6	12113.3	11140
NCDs		(83.8%)	(88.2%)	(86.3%)	(80.3%)	(75.1%)
Major		1807.8	1878.0	1706.1	1906.2	1682.6
NCDs		(12.8%)	(12.9%)	(13.2%)	(12.6%)	(11.3%)
	Cancers	137.7	244.4	133.9	73.9	68.9
	Cancers	(1.0%)	(1.7%)	(1.0%)	(0.5%)	(0.5%)
	CVD	511.3	420.2	563.6	496.8	520.6
	CVD	(3.6%)	(2.9%)	(4.4%)	(3.3%)	(3.5%)
	CRD	463.5	508.5	357.4	576.6	480
	CRD	(3.3%)	(3.5%)	(2.8%)	(3.8%)	(3.2%)
	Diabetes	695.3	704.9	651.2	758.9	613.1
	mellitus	(4.9%)	(4.8%)	(5.0%)	(5.0%)	(4.1%)


HALE_{[30-70)} = health adjusts life expectancy for people aged 30-70; YLDs = years lived with disability; NCDs = non-communicable diseases; CVD = cardiovascular diseases; CRD = chronic respiratory diseases

252

Potential gains in health-adjusted life expectancy for people aged 30-70 in alternative future scenarios


In all scenarios, the high-income group has the greatest potential gains in $HALE_{[30-70]}$, above

256	the global average. For all specific causes, potential gains in $HALE_{[30-70)}$ decreases as income
257	levels fall. In scenario A, the potential gains in $HALE_{[30-70)}$ of reducing premature mortality for
258	four major NCDs are significantly lower than for all NCDs (range of difference for all income
259	groups: 2.88 - 3.27 years). In scenario B and scenario C, the potential gains of $HALE_{[30-70)}$ in
260	reducing premature mortality for all NCDs and the four major NCDs are very close (scenario
261	B: 0.14 - 0.22, scenario C: 0.05 - 0.19). In scenarios A and B, the high-income group has the
262	greatest potential gains in $HALE_{[30-70)}$ from cancer intervention, and the other income groups
263	have the greatest potential gains in HALE _{[30-70)} from cardiovascular diseases intervention. In
264	scenario C, all income groups have the greatest potential gains in $HALE_{[30-70)}$ from diabetes
265	and chronic respiratory diseases (figure 3).




266

267 Fig.3 For specific non-communicable diseases, potential gains in health-adjusted life




269

270	For four major NCDs, reaching scenario A is estimated to yield fewer potential gains of
271	$\mathrm{HALE}_{[30-70)}$ in several Southern Africa and Middle Africa regions, including the Central African
272	Republic and Niger. The Pacific island states, including Fiji, Guam, Solomon Islands, and
273	Kiribati, in addition to the United States of America, have the larger benefits. Achieving
274	scenario B is estimated to yield higher potential gains of HALE _{[30-70)} in the United States of
275	America, Australia, Canada, Japan, Iceland, New Zealand, and Kuwait, but some African
276	regions, such as Lesotho and the Central African Republic, have lower potential gains of
277	$HALE_{[30-70]}$. In scenario C, $HALE_{[30-70]}$ will show negative growth in some African and Pacific
278	island states, including Solomon Islands, Kiribati, Uzbekistan, Micronesia (Fed. States of),
279	Lesotho, and the Central African Republic. By contrast, $HALE_{[30-70)}$ is still growing
280	aggressively in certain American, European, and Asian countries, such as Australia, Japan,
281	Iceland, United States of America, Canada, Switzerland, Luxembourg, Republic of Korea, New
282	Zealand, Kuwait, Italy, Norway, Singapore, Colombia, Puerto Rico, Spain, and France (figure
283	4). For all NCDs, four major NCDs, and the individual major NCDs, potential gains in
284	$HALE_{[30-70)}$ with 95% UIs are provided in the appendix (table S3, table S4, and table S5).



Potențial gains in HALE_{p0-70} (years) 1.0 to <2.0 2.0 to <3.0 3.0 to <4.0 4.0 to <5.0 5.0 to <6.0 NA

Scenario C



285

Fig.4 For four major non-communicable diseases, potential gains in health-adjusted life

287 expectancy for people aged 30-70 in alternative future scenarios

288

289 Discussion

290	Our results highlight the significant gains in $HALE_{[30-70)}$ worldwide on top of achieving SDGs
291	target 3.4, enabling survivors to rehabilitation from disability, which reflects the current high
292	premature mortality burden and disability burden of NCDs worldwide and the effect that efforts
293	to reduce it could have. However, based on trends in premature mortality over the past three
294	decades, we found that it seems impossible for most countries to reduce premature mortality
295	from four major NCDs to two-thirds of the 2015 baseline within the 10-year window. To our
296	knowledge, this is the first global study to assess the potential gains for $HALE_{[30-70)}$ by reducing
297	premature death and disability as a whole and attaching equal importance to each. This study
298	highlights the limitations of the current framework from a visionary perspective and points
299	toward future directions for necessary global health policy with broadened scope. Our results
300	reinforce the urgency of meeting SGDs target 3.4 and highlight the importance of reducing
301	disability to improve quality of life.

302 We found HALE_[30-70] in high- and upper-middle-income countries were higher than that in 303 lower-middle- and low-income countries in 2015, but the gaps between high- and low-income countries in age-standardized YLDs were small. Current demographic and health risk changes 304 305 have resulted in an increase in disability and an earlier onset of disability. The increase in the 306 number of total YLDs is significant in the context of population aging and health risk shifts^[29]. However, a horizontal comparison of HALE based on life expectancy between countries at 307 different economic levels does not reflect the lack of disability rehabilitation, as developed 308 countries have a higher life expectancy^[30]. The increase in the number of total YLDs may 309 burden economies and healthcare systems as the systems have not kept up with population 310

311 growth^[31]. Reducing premature mortality and disability requires enhancing primary care and scale-up rehabilitation, driven by significant population aging and increased demand for long-312 term care^[32-34]. Generally, Integrating rehabilitation into primary health care is limited in lower-313 middle- and low-income countries, while high- and upper-middle-income countries do better^{[35-} 314 315 ^{37]}. However, our results suggest that there is still a need for health policies in developed 316 countries to expand the coverage and willingness of rehabilitation and benefit more people. Although 80% of NCDs occurred in lower-middle- and low-income countries^[7], we observed 317 that the potential gains in $HALE_{[30-70)}$ from reducing premature mortality and disability for the 318 319 four major NCDs are highest in high-income countries. The potential contributing factors may 320 be a decrease in poverty-related risk factors and an increase in behavioral risk factors, such as tobacco consumption, harmful use of alcohol, and unhealthy diet^[9,38-41]. The four major NCDs 321 322 have received attention due to their high prevalence and high mortality rates. Excessive premature mortality indicates early age of disease, rapid course of the disease, and poor 323 prognosis, and most of them are accompanied by severe complications. Surviving patients must 324 325 continue to live with the disease, develop new life routines, and adapt to the changes in health status, which means they have a higher disability weight and more disability life years lost. 326 327 NCDs are long-term or lifelong, and a person cannot hold a temporary "patient role" and then recover. In addition to socio-economic effects, exposure to products that are harmful to health 328 or unhealthy eating habits can also increase the risk of NCDs^[2,42,43]. NCDs can be controlled by 329 reducing the risk factors associated with these diseases, and guiding policy and priorities by 330 governments and other stakeholders are essential^[2]. It is recommended that lower-middle- and 331 low-income countries integrate rehabilitation into primary health care, while high- and upper-332

middle-income countries focus on improving behavioral risk factors while ensuring that sound
 rehabilitation and care benefit everyone.

335 Our results revealed estimates of what individual countries in four income groups might achieve in controlling premature mortality in four major NCDs by 2030, which will provide 336 337 policymakers with experience from leading countries and evidence on health policy. Some 338 European countries are expected to do better in controlling NCDs' premature mortality, and these countries are considered similar in terms of social structure and culture^[44]. The Nordic 339 340 welfare states have a long-standing commitment to egalitarian welfare policies that have helped 341 to achieve significant improvements in the health of covered all social groups^[44,45]. The WHO European Region has mapped the lessons to the Consolidated Framework for Implementation 342 Research to support increasing coverage of quality essential health services in member states 343 with the lowest resources^[46]. In lower-middle- and low-income countries, priorities for the 344 prevention and control of NCDs compete with other important agendas such as poverty 345 346 eradication and environmental protection. It is encouraging that the UN and WHO are actively 347 working to combat the disease burden of NCDs in less developed regions and that NCDs-related strategies such as Universal Health Coverage and Best Buy are integrated into primary health 348 care^[47]. But few countries met the recommended levels, and there is a lack of adequate 349 evaluation of many well-developed interventions^[48,49]. NCDs are killing and disabling people 350 at their peak productivity and are already another "poverty trap" on par with infectious 351 diseases^[50]. A substantial proportion of NCDs among adults could be prevented by early 352 353 screening and self-management, but lower-middle- and low-income countries appear to have not fully adopted cost-effective strategies, possibly limited by the affordability and accessibility 354

of health care^[37,51]. 355

369

370

356	This study has several strengths. First, we provided a trend analysis of regional and country-
357	level NCDs from a global health perspective and an intuitive assessment of progress towards
358	meeting SDGs target 3.4. Secondly, we expanded on SDGs target 3.4 of focusing on reducing
359	disability in survivors and reducing premature mortality, which is a key step toward reducing
360	the disease burden of NCDs. Third, the data sources for our study were estimates modeled from
361	the best available evidence and research, which be viewed as the best current estimate. Open
362	access databases of GBD across locations and the entire time series will be re-estimated by
363	relevant study collaborators each new cycle using the latest datasets and more advanced
364	modeling methods.
365	This study has at least two limitations. First, for individual NCDs, our analysis did not consider
366	causes beyond the four main NCDs. We limited our analysis to four major NCDs because they
367	are the leading cause of premature death, in line with the SDG target 3.4 emphasizes reducing
368	premature death. Further studies will take into account more NCDs with low mortality but a

gains in HALE_[30-70], we converted YLLs to YLDs in equal proportions. For some causes and

higher disease burden for survivors. Second, in the hypothetical scenario of estimating potential

their sequelae, current medical techniques may be difficult to relieve unbearable physical and 371

372 mental suffering while extending life. Disability weights and YLDs may be underestimated.

Therefore, our results are conservative estimates of potential gains of HALE_[30-70]. 373

In conclusion, our findings show that meeting SDGs target 3.4 remains challenging for most 374

countries. Currently, the health life-year loss due to NCDs is highest in high-income countries. 375

The elimination of survivor disability from the SDG target 3.4 could lead to a sizable 376

377	improvement in average health-adjusts life expectancy lived for people aged 30 to70 years by
378	2030. We call on governments to make robust public health interventions and adequate
379	consideration of the independent or combined effects of health drivers, including health risk
380	factors, interventions, and broader sociodemographic and health system factors, to ensure that
381	health resources are properly distributed and available to all, especially to those most in need ^[52] .
382	
383	Acknowledgments
384	The most important acknowledgment is to the GBD 2019 Diseases and Injuries Collaborators,
385	as well as to all the participants included in the study. The authors alone are responsible for the
386	views expressed in this article and they do not necessarily represent the views, decisions, or
387	policies of the institutions with which they are affiliated.
388	Competing interests
	Competing interests
389	No competing interests were declared.
389 390	
	No competing interests were declared.
390	No competing interests were declared. Author contributions
390 391	No competing interests were declared. Author contributions Jun-Yan Xi: Conceptualization; Data curation; Software; Formal analysis; Investigation;
390 391 392	No competing interests were declared. Author contributions Jun-Yan Xi: Conceptualization; Data curation; Software; Formal analysis; Investigation; Visualization; Methodology; Writing - original draft. Wang-Jian Zhang: Formal analysis;
390 391 392 393	No competing interests were declared. Author contributions Jun-Yan Xi: Conceptualization; Data curation; Software; Formal analysis; Investigation; Visualization; Methodology; Writing - original draft. Wang-Jian Zhang: Formal analysis; Validation; Writing - review and editing. Zhuo Chen: Formal analysis; Validation; Writing -
390 391 392 393 394	No competing interests were declared. Author contributions Jun-Yan Xi: Conceptualization; Data curation; Software; Formal analysis; Investigation; Visualization; Methodology; Writing - original draft. Wang-Jian Zhang: Formal analysis; Validation; Writing - review and editing. Zhuo Chen: Formal analysis; Validation; Writing - review and editing. Yan-Ting Zhang: Investigation; Visualization; Methodology. Li-Chang

- 397 Methodology; Project administration; Writing review and editing. Yuan-Tao Hao:
- 398 Conceptualization; Resources; Supervision; Funding acquisition; Methodology; Project

administration; Writing – review and editing.

400 Data availability statement

- 401 The full dataset in this study can be obtained from the Institute for Health Metrics and
- 402 Evaluation (https://www.healthdata.org/) and World Population Prospects 2019
- 403 (https://population.un.org/wpp/). All data generated during this study are included in the
- 404 manuscript and supporting files.
- 405 Ethics
- 406 The requirement for ethical board approval was waived because this study is secondary data
- 407 analysis. All data were aggregated and did not contain any information at the individual
- 408 levels. Therefore, there were no specific ethical issues warranted special attention.

409

410	References
411	1. World Health Statistics. World Health Statistics 2021.
412	https://apps.who.int/iris/bitstream/handle/10665/342703/9789240027053-eng.pdf. accessed
413	December 1, 2021
414	2. World Health Organization. Noncommunicable diseases. https://www.who.int/news-
415	room/fact-sheets/detail/noncommunicable-diseases. accessed December 1, 2021
416	3. United Nations. Transforming our World: The 2030 Agenda for Sustainable Development.
417	https://sustainabledevelopment.un.org/post2015/transformingourworld/publication. accessed
418	December 1, 2021
419	4. NCD Countdown Collaborators. NCD Countdown 2030. https://ncdcountdown.org/.
420	accessed December 1, 2021
421	5. Bennett JE, Stevens GA, Mathers CD, et al. NCD Countdown 2030: worldwide trends in
422	non-communicable disease mortality and progress towards Sustainable Development Goal
423	target 3.4. The Lancet. 2018; 392: 1072-88.
424	6. Nugent R, Bertram MY, Jan S, et al. Investing in non-communicable disease prevention
425	and management to advance the Sustainable Development Goals. The Lancet. 2018; 391: 2029-
426	35.
427	7. Niessen LW, Mohan D, Akuoku JK, et al. Tackling socioeconomic inequalities and non-
428	communicable diseases in low-income and middle-income countries under the Sustainable
429	Development agenda. The Lancet. 2018; 391: 2036-46.
430	8. Magnusson RS. Framework legislation for non-communicable diseases: and for the
431	Sustainable Development Goals? BMJ Global Health. 2017; 2: e385.

	432	9.	Cao B	, Bray	F,	, Ilbawi A.	, et al.	Effect	on	longevity	of	one-third	reduction	in	prematur
--	-----	----	-------	--------	----	-------------	----------	--------	----	-----------	----	-----------	-----------	----	----------

433 mortality from non-communicable diseases by 2030: a global analysis of the Sustainable

- 435 10. Martinez R, Lloyd-Sherlock P, Soliz P, et al. Trends in premature avertable mortality from
- 436 non-communicable diseases for 195 countries and territories, 1990 2017: a population-based
- 437 study. The Lancet Global Health. 2020; 8: e511-23.
- 438 11. Zhou T, Guan H, Yao J, et al. The quality of life in Chinese population with chronic non-
- 439 communicable diseases according to EQ-5D-3L: a systematic review. QUAL LIFE RES. 2018;
- 440 27: 2799-814.
- 12. Van Wilder L, Clays E, Devleesschauwer B, et al. Health-related quality of life in patients
- with non-communicable disease: study protocol of a cross-sectional survey. BMJ OPEN. 2020;
 10: e37131.
- 444 13. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204
- 445 countries and territories, 1990 2019: a systematic analysis for the Global Burden of Disease
 446 Study 2019. The Lancet. 2020; 396: 1204-22.
- 447 14. Wang H, Abbas KM, Abbasifard M, et al. Global age-sex-specific fertility, mortality,
- 448 healthy life expectancy (HALE), and population estimates in 204 countries and territories,
- 449 1950 2019: a comprehensive demographic analysis for the Global Burden of Disease Study
- 450 2019. The Lancet. 2020; 396: 1160-203.
- 451 15. Murray CJL, Aravkin AY, Zheng P, et al. Global burden of 87 risk factors in 204 countries
- 452 and territories, 1990 2019: a systematic analysis for the Global Burden of Disease Study 2019.
- 453 The Lancet. 2020; 396: 1223-49.

⁴³⁴ Development Goal health target. The Lancet Global Health. 2018; 6: e1288-96.

454	16. University of Washington, Institute for Health Metrics and Evaluation. Global Burden of
455	Disease (GBD 2019). http://www.healthdata.org/gbd/2019. accessed December 1, 2021
456	17. Ševcíková H, Raftery AE. bayesPop: Probabilistic Population Projections. J STAT
457	SOFTW. 2016; 75.
458	18. Raftery AE, Alkema L, Gerland P. Bayesian Population Projections for the United Nations.
459	STAT SCI. 2014; 29: 58-68.
460	19. United Nations, Department of Economic and Social Affairs, Population Division.
461	Probabilistic Population Projections Rev. 1 based on the World Population Prospects 2019.

- 462 https://population.un.org/wpp/Download/Probabilistic/Population/. accessed December 1,
- 463 2021
- 464 20. World Bank. World Bank Country and Lending Groups.
- 465 https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-
- 466 lending-groups. accessed December 1, 2021
- 467 21. Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health
- 468 Estimates Reporting: the GATHER statement. The Lancet. 2016; 388: e19-23.
- 469 22. Riebler A. BAPC: Projection of cancer incidence and mortality data using Bayesian APC
- 470 models fitted with INLA. https://rdrr.io/rforge/BAPC/. accessed December 1, 2021
- 471 23. Riebler A, Held L. Projecting the future burden of cancer: Bayesian age-period-cohort
- analysis with integrated nested Laplace approximations. BIOMETRICAL J. 2017; 59: 531-49.
- 473 24. Schmid VJ, Held L. Bayesian Age-Period-Cohort Modeling and Prediction -BAMP. J
- 474 STAT SOFTW. 2007; 21.
- 475 25. Tsai SP, Lee ES, Hardy RJ. The effect of a reduction in leading causes of death: potential

476 gains in life expectancy. American journal of public health (1971). 1978; 68: 966-71.

- 477 26. Eavres D, Williams ES. Evaluation of methodologies for small area life expectancy
- 478 estimation. Journal of epidemiology and community health (1979). 2004; 58: 243-49.
- 479 27. Hu X, Sun X, Li Y, et al. Potential gains in health-adjusted life expectancy from reducing
- 480 four main non-communicable diseases among Chinese elderly. BMC GERIATR. 2019; 19: 16.
- 481 28. Wang GD, Lai DJ, Burau KD, et al. Potential gains in life expectancy from reducing heart
- 482 disease, cancer, Alzheimer's disease, kidney disease or HIV/AIDS as major causes of death in
- 483 the USA. PUBLIC HEALTH. 2013; 127: 348-56.
- 484 29. Cieza A, Causey K, Kamenov K, et al. Global estimates of the need for rehabilitation based
- 485 on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of
- 486 Disease Study 2019. The Lancet. 2020; 396: 2006-17.
- 487 30. Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-
- 488 cause mortality, and cause-specific mortality for 249 causes of death, 1980 2015: a systematic
- analysis for the Global Burden of Disease Study 2015. The Lancet. 2016; 388: 1459-544.
- 490 31. James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence,
- 491 and years lived with disability for 354 diseases and injuries for 195 countries and territories,
- 492 1990 2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet.
- 493 2018; 392: 1789-858.
- 494 32. Anton SD, Woods AJ, Ashizawa T, et al. Successful aging: Advancing the science of
- 495 physical independence in older adults. AGEING RES REV. 2015; 24: 304-27.
- 496 33. Crocker T, Forster A, Young J, et al. Physical rehabilitation for older people in long-term
- 497 care. COCHRANE DB SYST REV. 2013: D4294.

- 498 34. Forster A, Lambley R, Young JB. Is physical rehabilitation for older people in long-term
- 499 care effective? Findings from a systematic review. AGE AGEING. 2010; 39: 169-75.
- 500 35. Abreu A, Pesah E, Supervia M, et al. Cardiac rehabilitation availability and delivery in
- 501 Europe: How does it differ by region and compare with other high-income countries? EUR J
- 502 PREV CARDIOL. 2019; 26: 1131-46.
- 503 36. Thornicroft G, Ahuja S, Barber S, et al. Integrated care for people with long-term mental
- and physical health conditions in low-income and middle-income countries. The Lancet
- 505 Psychiatry. 2019; 6: 174-86.
- 506 37. Hearn J, Ssinabulya I, Schwartz JI, et al. Self-management of non-communicable diseases
- in low- and middle-income countries: A scoping review. PLOS ONE. 2019; 14: e219141.
- 508 38. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and
- 509 mortality in 155 722 individuals from 21 high-income, middle-income, and low-income
- 510 countries (PURE): a prospective cohort study. The Lancet. 2020; 395: 795-808.
- 511 39. Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and
- 512 deaths attributable to potentially modifiable risk factors in the United States. CA: A Cancer
- 513 Journal for Clinicians. 2018; 68: 31-54.
- 40. Grant BF, Chou SP, Saha TD, et al. Prevalence of 12-Month Alcohol Use, High-Risk
- 515 Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013.
- 516 JAMA PSYCHIAT. 2017; 74: 911.
- 517 41. Cena H, Calder PC. Defining a Healthy Diet: Evidence for the Role of Contemporary
- 518 Dietary Patterns in Health and Disease. NUTRIENTS. 2020; 12: 334.
- 42. Afshin A, Sur PJ, Fay KA, et al. Health effects of dietary risks in 195 countries, 1990 -

520 2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2019;

521 393: 1958-72.

- 522 43. Licher S, Heshmatollah A, van der Willik KD, et al. Lifetime risk and multimorbidity of
- 523 non-communicable diseases and disease-free life expectancy in the general population: A
- 524 population-based cohort study. PLOS MED. 2019; 16: e1002741.
- 525 44. Balaj M, Huijts T, McNamara CL, et al. Non-communicable diseases and the social
- 526 determinants of health in the Nordic countries: Findings from the European Social Survey
- 527 (2014) special module on the social determinants of health. SCAND J PUBLIC HEALT. 2017;
- 528 45: 90-102.
- 529 45. Thomson KH, Renneberg A, McNamara CL, et al. Regional inequalities in self-reported
- 530 conditions and non-communicable diseases in European countries: Findings from the European
- 531 Social Survey (2014) special module on the social determinants of health. EUR J PUBLIC
- 532 HEALTH. 2017; 27: 14-21.
- 46. Collins D, Laatikainen T, Farrington J. Implementing essential interventions for cardiovascular disease risk management in primary healthcare: lessons from Eastern Europe and Central Asia. BMJ Global Health. 2020; 5: e2111.
- 536 47. Ganju A, Goulart AC, Ray A, et al. Systemic Solutions for Addressing Non-
- 537 Communicable Diseases in Low- and Middle-Income Countries. Journal of multidisciplinary
- 538 healthcare. 2020; Volume 13: 693-707.
- 48. Tesema AG, Ajisegiri WS, Abimbola S, et al. How well are non-communicable disease
- 540 services being integrated into primary health care in Africa: A review of progress against World
- 541 Health Organization's African regional targets. PLOS ONE. 2020; 15: e240984.

49. Allen LN, Pullar J, Wickramasinghe KK, et al. Evaluation of research on intervent	542	49. All	en LN, Pull	ar J. Wickramasing	ghe KK, et al.	Evaluation of	research on	intervention
---	-----	---------	-------------	--------------------	----------------	---------------	-------------	--------------

- 543 aligned to WHO 'Best Buys' for NCDs in low-income and lower-middle-income countries:
- a systematic review from 1990 to 2015. BMJ Global Health. 2018; 3: e535.
- 545 50. STUCKLER D. Population Causes and Consequences of Leading Chronic Diseases: A
- 546 Comparative Analysis of Prevailing Explanations. The Milbank Quarterly. 2008; 86: 273-326.
- 547 51. Fidler MM, Gupta S, Soerjomataram I, et al. Cancer incidence and mortality among young
- adults aged 20 39 years worldwide in 2012: a population-based study. The Lancet Oncology.
- 549 2017; 18: 1579-89.
- 550 52. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost,
- and all-cause and cause-specific mortality for 250 causes of death: reference and alternative
- scenarios for 2016 40 for 195 countries and territories. The Lancet. 2018; 392: 2052-90.